Aberrant activation of the Hedgehog signalling pathway in squamous cell carcinoma of the vulva as a potential target for cancer therapy

• Published in: Scientific reports Vol. 11; no. 1; p. 17665
• Main Authors: Yap, Jason K. W., Uddin, Khalil, Pounds, Rachel, O’Neill, Danielle, Kehoe, Sean, Ganesan, Raji, Dawson, Christopher W.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 03-09-2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67; 631/67/1059; 631/67/1517; 631/67/395; 692/4028; Cancer therapies; Cell activation; Cell culture; Cell growth; Cell proliferation; Chemotherapy; Cisplatin; Epithelium; Genital cancers; Hedgehog protein; Humanities and Social Sciences; Itraconazole; Kinases; Ligands; multidisciplinary; Point mutation; Science; Science (multidisciplinary); Signal transduction; siRNA; Squamous cell carcinoma; Vulva
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-96940-1

In a previous study, we showed that the Hedgehog (Hh) signalling pathway is aberrantly activated in vulval squamous cell carcinoma (VSCC). In this study, we further validated our findings on a prospective cohort of primary VSCC cases, where immunohistochemical staining confirmed that key Hh pathway components were overexpressed in VSCC compared to normal vulval epithelium. We also undertook a series of in vitro studies to determine the extent of Hh pathway activation in VSCC-derived cell lines, and examine the consequences of pathway inhibition on the growth of these cells. We found that of six cell lines tested, four displayed elevated baseline Hh pathway activity that was dependent on SHH ligand, or in one case, a
PTCH1
gene mutation. Hh signalling appeared necessary to sustain cell growth, as SHH ligand depletion with Robotikinin or SMO inhibition, either with chemical inhibitors (Itraconazole or LDE-225) or SMO-specific siRNA, attenuated GLI1 activity and cell proliferation in both monolayer and organotypic raft culture. Furthermore, treatment of Hh-dependent cell lines with SMO inhibitors sensitised cells to Cisplatin. Findings from our study offer us the opportunity to explore further the development of targeted chemotherapy for women with VSCC driven by aberrant Hh activation.